Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.

Jason John Luke Sarina A Piha-Paul Theresa M Medina Claire F Verschraegen Mary Varterasian Aoife M Brennan Richard J Riese Anna Sokolovska James F Strauss David L Hava Filip Janku

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Repeat intratumoral injection of SYNB1891 as monotherapy and in combination with atezolizumab was safe and well tolerated, and evidence of STING pathway target engagement was observed.

Keyphrases

escherichia coli
social media
clinical trial
combination therapy